Allogene Therapeutics, Inc. SEC filings ALLO

Allogene Therapeutics, Inc. has 585 filings in SEC EDGAR's recent list, going back to Apr 19, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 30, 2026 Dec 31, 2025
10-K Annual report Mar 12, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 30, 2025 Dec 31, 2024
10-K Annual report Mar 13, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 23, 2024 Dec 31, 2023
10-K Annual report Mar 14, 2024 Dec 31, 2023
10-K/A Amended annual report Mar 14, 2024 Dec 31, 2022
ARS Annual report to shareholders Apr 24, 2023 Dec 31, 2022
10-K Annual report Feb 28, 2023 Dec 31, 2022
10-K Annual report Feb 23, 2022 Dec 31, 2021
10-K Annual report Feb 25, 2021 Dec 31, 2020
10-K Annual report Feb 27, 2020 Dec 31, 2019
10-K Annual report Mar 8, 2019 Dec 31, 2018

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ALLO (Nasdaq)
Fiscal year ends
December 31
Headquarters
South San Francisco, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1737287

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.